Jie Lun Zhu
Fondateur chez Vivere Lifesciences Acquisition Corp.
Profil
Jie Lun Zhu has founded Vivere Lifesciences Acquisition Corp.
in 2022, where he currently holds the position of Executive Director & Chief Investment Officer.
Mr. Zhu's former jobs include being MD & Head-Healthcare Investment Banking at Jefferies Hong Kong Ltd.
from 2015 to 2018, and Chief Financial Officer at I-MAB Biopharma Co., Ltd.
Mr. Zhu's education history includes an undergraduate degree from Wesleyan University and an MBA from Harvard Business School.
Postes actifs de Jie Lun Zhu
| Sociétés | Poste | Début |
|---|---|---|
Vivere Lifesciences Acquisition Corp.
 Vivere Lifesciences Acquisition Corp. Financial ConglomeratesFinance Vivere Lifesciences Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Siu Wai Ng, Jie Lun Zhu and Ya Chun Chen on February 8, 2022 and is headquartered in Hong Kong. | Fondateur | 08/02/2022 |
Anciens postes connus de Jie Lun Zhu
| Sociétés | Poste | Fin |
|---|---|---|
Jefferies Hong Kong Ltd.
 Jefferies Hong Kong Ltd. Investment Banks/BrokersFinance Jefferies Hong Kong Ltd. is a securities brokerage firm headquartered in Hong Kong. The firm is a subsidiary of Jefferies Group LLC, which is owned by Jefferies Financial Group, Inc. (NYSE: JEF) in the US. Jefferies Hong Kong is a client-focused full-service sales, trading and capital markets platform across all equity and fixed income securities. They provide an array of trading and execution services for their clients. | Corporate Officer/Principal | 01/07/2018 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Directeur Financier/CFO | - |
Formation de Jie Lun Zhu
| Harvard Business School | Masters Business Admin |
| Wesleyan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
Vivere Lifesciences Acquisition Corp.
Vivere Lifesciences Acquisition Corp. Financial ConglomeratesFinance Vivere Lifesciences Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Siu Wai Ng, Jie Lun Zhu and Ya Chun Chen on February 8, 2022 and is headquartered in Hong Kong. | Finance |
Jefferies Hong Kong Ltd.
Jefferies Hong Kong Ltd. Investment Banks/BrokersFinance Jefferies Hong Kong Ltd. is a securities brokerage firm headquartered in Hong Kong. The firm is a subsidiary of Jefferies Group LLC, which is owned by Jefferies Financial Group, Inc. (NYSE: JEF) in the US. Jefferies Hong Kong is a client-focused full-service sales, trading and capital markets platform across all equity and fixed income securities. They provide an array of trading and execution services for their clients. | Finance |